看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
' t7 R6 Q6 Q. z- B1 ]
: [! H$ a. |: ^0 h0 x+ E7 w- X# E1 H) r9 ~& f5 l* Q7 V
Currently available feasibility data for possible combination strategies. # N* E, J+ ^) f/ G
————————————————————————————————+ e- t" X9 {& R' T
Combination Feasibility according to preliminary data
3 O2 ]: ^$ V6 S& q; i——————————————————————————————————
7 y0 P# h! s. d" a$ {# rBevacizumab + sorafenib Yes, reduced dose & o: B# w4 _8 c% R1 a6 i
Bevacizumab + sunitinib† No ) A" W8 b, X( W( }- D
Bevacizumab + temsirolimus Yes ) S% s7 c, ?4 V# }" u
Bevacizumab + everolimus Yes
- c& Q; d/ d( G8 ^8 e: sSorafenib + sunitinib ? ' Y. ]8 a0 {1 t1 \% W
Sorafenib + temsirolimus Yes, reduced dose
, u9 Y# I. |! a& Z7 X0 A9 }Sorafenib + everolimus Yes, reduced dose
7 V( I9 Y$ ^& Q/ `9 s6 `Sunitinib + temsirolimus† No , L* \$ x% d% o% q7 j
Sunitinib + everolimus ?
8 b3 V7 z, d* P% e7 d# RTemsirolimus + everolimus ? % p9 k8 w. R. V6 W
————————————————————$ F! D5 o# z4 S- S' P: z+ x4 m9 b
†Led to US FDA warning.+ @" z+ Z) U* ^) H6 h5 w
?: As yet unattempted combination.
6 k9 @9 m3 K! m7 Y) \ |